Renal-cell cancer

Clinical trials showed therapeutic efficacy in a broad spectrum of tumors these include SCLC, testicular tumors, sarcomas, breast cancer, renal cell cancer, pancreatic tumors and lymphomas. Ifosfamide is less myelosuppressive than cyclophosphamide but is more toxic to the bladder. Therefore it is recommended that ifosfamide is coadministered with the thiol compound mesna to avoid hemorrhagic cystitis and to reduce the risk of developing bladder cancer. Other side effects include neurotoxicity and myelosuppression. [Pg.55]

VHL Regulator of protein stability Renal cell cancer... [Pg.1279]

Sorafenib is a multikinase inhibitor that inhibits both intracellular and extracellular kinases to decrease renal cell cancer proliferation. The half-life of sorafenib is 25 to 48 hours, with a bioavailability of 38% to 49% and a time to peak concentration of 3 hours. Sorafenib is metabolized primarily by the liver by CYP450 3A4. Sorafenib is used for the treatment of renal cell cancer. The primary side effects of sorafenib include rash, hand-foot skin reaction, diarrhea, pruritus, and elevations in serum lipase. [Pg.1295]

Braybrooke JP, Vallis KA, Houlbrook S, Rockett H, Ellmen J, Anttila M, Ganesan TS, Harris AL, Talbot DC (2000) Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol 46(1) 27—34... [Pg.109]

Melanoma renal cell cancer Melanoma renal cell cancer Head and neck, lung, and breast cancer Hepatitis C... [Pg.148]

Sleijfer, D.T. et al., Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis, J. Clin. Oncol., 10, 1119, 1992. [Pg.168]

In summary, these three approvals with the noncytotoxic monoclonal antibodies demonstrated activity based on survival (Avastin), TIP in an enriched population (Avastin in renal cell cancer), a pure response with endpoint (Campath), and a clever response rate to a combination vs. a reference point response rate with that new agent alone (Cetuximab). [Pg.451]

Proleukin is a recombinant form of IL-2. It is approved for the treatment of malignant melanoma and renal cell cancer. Ontak (denileukin diftitox) is a fusion protein for the treatment of persistent or recurrent T-cell lymphoma. Activated T cells express lL-2 receptors. Ontak has a fragment that binds to the IL-2 receptor while the other part presents a diphtheria toxin to kill the activated T cell. [Pg.117]

There are limited epidemiological data regarding carcinogenicity in humans following chronic inhalation exposure to kerosene. In one case-control study, there was no association between the use of kerosene stoves for cooking and bronchial cancer in nonsmoking women (Chan et al. 1979). In another case-control study, there was no association between renal cell cancer and occupational exposure to fuel oils. [Pg.46]

Partanen T, Heikkila P, Hernberg S, et al. 1991. Renal cell cancer and occupational exposure to chemical agents. Scan J Work Environ Health 17(4) 231-239. [Pg.189]

It does not appear that the nephrotoxicity attributable to a2u-globulin syndrome is relevant to humans. Most epidemiological studies have not shown an association between gasoline exposure and renal cancer risk. However, a recent case-control study from Finland reported a significant association between renal cell cancer and gasoline that was dose dependent."... [Pg.357]

Mclaughlin JK Renal cell cancer and exposure to gasoline a review. Environ Health Perspect 101(suppl 6) 111-114, 1993... [Pg.357]

Aldesleukin is a recombinant form of human Interleukin-2 (IL-2). It has been approved for the treatment of malignant melanoma and renal cell cancer. The medicine is administered every 8 hours by a 15-minute intravenous infusion for a maximum of 14 doses. Adverse reactions include hypo- and hypertension, gastrointestinal disturbances, fever, fatigue, lethargy, joint pain, headache. Cardiovascular problems may occur. [Pg.461]

Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V McGrath PC et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001 345 1655-9. [Pg.725]

Goey SH, Verweij J, Stoter G. Immunotherapy of metastatic renal cell cancer. Ann Oncol 1996 7 887-900. [Pg.725]

Unlabeled Uses Treafmenf of germ cell cancer, ovarian cancer, pancreatic cancer, renal cell cancer, solid tumors... [Pg.912]

It is used for the treatment of non small cell lung carcinoma, breast carcinoma, Hodgkin s disease, ovarian carcinoma, squamous cell carcinoma of the head and neck, cervical squamous cell carcinoma, renal cell cancer and Kaposi s sarcoma. [Pg.377]

Hussain M, Vaishampayan U, Heilbrun LK, Jain V, LoRusso PM, Ivy P, Flaherty L (2003) A Phase II Study of Rebeccamycin Analog (NSC-655649) in Metastatic Renal Cell Cancer. Invest New Drugs 21 465... [Pg.446]

D.R. Parkinson, C.A. Seipp, J.H. Ein-horn, and D.E. White. 1994. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271 907-913. [Pg.324]

In the dose-escalation studies, PK data were obtained for patients with a variety of EGFR-expressing solid cancers, while the studies at the approved dosing regimen were conducted in the indications of colorectal carcinoma, squamous cell cancer of the head-and-neck, pancreatic cancer, and renal cell cancer. [Pg.356]

Punt CJ, Voest EE, Tueni E, et al. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer. Br J Cancer 1997 76(10) 1376-1381. [Pg.426]

Titanocenes Cytotoxic and Anti-angiogenic Chemotherapy Against Advanced Renal-Cell Cancer... [Pg.119]

Schlehofer, B., Pommer, W., Mellemgaard, A., Stewart, J. H., McCredie, M., etal., International renal-cell-cancer study. VI. The role of medical and family history. Int. J. Cancer 66,723-726 (1994). [Pg.59]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...